In this large population-based series of colorectal cancers (CRC), in which we previously validated the independent negative prognostic value of our H&E-based biomarker SARIFA (Stroma AReactive Invasion Front Areas),30 we now investigated whether the strong prognostic value of SARIFA-status remains within molecular subgroups based on BRAF, RAS, and MMR status and whether﻿ SARIFA-positivity is associated with a differential response to adjuvant therapy. This evidence concerns the gene BRAF and colorectal carcinoma.